A Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor
Brief description of study
The Exablate Model 4000 Type-1.0/1.1 Neuro system involves using an advanced, non-invasive technique currently approved by the Food and Drug Administration (FDA) to treat one side of your brain in a procedure called a thalamotomy (lesion the thalamus). This procedure involves performing an ablation (lesion) of an area of the thalamus (a region in your brain) essential for treating Essential Tremor.
While treating one side of the brain works well for patients that have a tremor dominance on one side of their body, patients that are bilaterally (both sides) affected with Essential Tremor may desire a bilateral treatment.
This trial is being offered to Penn Medicine patients that have been diagnosed with Essential Tremor and previously completed an Exablate Index Procedure to treat their Essential Tremor.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Essential Tremor
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 834897
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
